Jianxiang Wang, Dr
Institute of Hematology & Blood Diseases Hospital, China
Emerging Leaders
not ranked
Current Leaders
#4840 pts
All-Time Leaders
#79622 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2014. 14 trials as lead/chair. How it works →
Trials led — by scientific impact
Efficacy and Safety of Low-dose Chemotherapy Combined With Immuno-targeted Drugs in Newly Diagnosed Adult Patients With Ph-negative B-cell Acute Lymphocytic Leukemia: A Prospective, Single-arm Clinical Study
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
6
impact
Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2RecruitingJuventas Cell Therapy Ltd.
5
impact
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
4
impact
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia
N/ARecruitingInstitute of Hematology & Blood Diseases Hospital, China
2
impact
CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
Phase 1CompletedInstitute of Hematology & Blood Diseases Hospital, China
2
impact
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Phase 2CompletedInstitute of Hematology & Blood Diseases Hospital, China
1
impact
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Prospective, Single-arm, Single-center Clinical Trial
Phase 2CompletedInstitute of Hematology & Blood Diseases Hospital, China
1
impact
Efficacy and Safety of Molecular Targeted Therapy Combined With Chemotherapy and Sequential CAR-T Cells in Newly Diagnosed Adult Patients With Philadelphia Chromosome-Positive B-cell Acute Lymphoblastic Leukemia
N/ARecruitingInstitute of Hematology & Blood Diseases Hospital, China
1
impact
An Open-label, Multi-center Phase Ib/II Study of MK-1045 (CN201) in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia
Phase 1RecruitingMSD R&D (China) Co., Ltd.
1
impact
Exploration of Efficacy and Safety of Adjunctive Methylene Blue in the Treatment of Immunotherapy-related CRS and ICANS: A Prospective, Single-arm, Phase I Clinical Study
Phase 1RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Universal CD7 CART (uCD7 CART) Cell Injection in the Treatment of Relapsed or Refractory CD7 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.
Phase 1RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Super-universal CD7 CART (supCD7 CART) Cell Injection in the Treatment of Relapsed or Refractory CD7 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Single-arm, Open-label, Dose Escalation and Expansion Phase I/II Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-814 Monotherapy and Combination Therapy in Patients With Hematological Malignancies
Phase 2RecruitingShenzhen TargetRx Co., Ltd.
0
impact
To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World
N/ARecruitingJuventas Cell Therapy Ltd.
0
impact
An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Monocytic Leukemia
N/ACompletedInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1CompletedJuventas Cell Therapy Ltd.
0
impact
Dasatinib Combined With Multi-agents Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Phase 1WithdrawnInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
Phase 2Enrolling by InvitationInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Efficacy and Safety of Chidamide in CBF Leukemia
Phase 2ActiveInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Efficacy of Decitabine in Clearance of MRD
Phase 2WithdrawnInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
Phase 3ActiveInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
Phase 2CompletedInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia
Phase 4CompletedInstitute of Hematology & Blood Diseases Hospital, China
0
impact